
PolyPid (PYPD) Stock Forecast & Price Target
PolyPid (PYPD) Analyst Ratings
Bulls say
PolyPid Ltd is a late-stage biopharmaceutical company specializing in PLEX-based therapies aimed at preventing surgical site infections (SSI), with its lead candidate D-PLEX100 showing promising efficacy-risk profiles in a Phase 3 clinical study involving colorectal cancer patients. Recently, the company announced a new financing agreement, facilitating the immediate exercise of outstanding warrants, which is expected to raise approximately $26.7 million, enhancing its financial resources for upcoming regulatory interactions. This capital influx positions PolyPid to potentially file a New Drug Application (NDA) for D-PLEX100 by the first half of 2026, further strengthening its pipeline and operational outlook.
Bears say
PolyPid Ltd faces significant risks related to the efficacy of its clinical-stage product candidates, as failure to deliver statistically significant results in studies could greatly diminish their potential value. Additionally, even successful clinical outcomes may not guarantee regulatory approval from domestic or foreign agencies, further jeopardizing the company's valuation. Compounded by complex patent procedures, potential revenue erosion has been anticipated starting in 2036, adding to the negative outlook on PolyPid’s stock.
This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.
PolyPid (PYPD) Analyst Forecast & Price Prediction
Start investing in PolyPid (PYPD)
Order type
Buy in
Order amount
Est. shares
0 shares